EP1601698A4 - Physiologically active polypeptide conjugate having prolonged in vivo half-life - Google Patents

Physiologically active polypeptide conjugate having prolonged in vivo half-life

Info

Publication number
EP1601698A4
EP1601698A4 EP04720540A EP04720540A EP1601698A4 EP 1601698 A4 EP1601698 A4 EP 1601698A4 EP 04720540 A EP04720540 A EP 04720540A EP 04720540 A EP04720540 A EP 04720540A EP 1601698 A4 EP1601698 A4 EP 1601698A4
Authority
EP
European Patent Office
Prior art keywords
life
prolonged
physiologically active
active polypeptide
vivo half
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04720540A
Other languages
German (de)
French (fr)
Other versions
EP1601698B1 (en
EP1601698A1 (en
Inventor
Young-Min Kim
Dae-Jin Kim
Sung-Min Bae
Chang-Ki Lim
Se-Chang Kwon
Gwan-Sun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd, Hanmi Pharmaceutical Industries Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of EP1601698A1 publication Critical patent/EP1601698A1/en
Publication of EP1601698A4 publication Critical patent/EP1601698A4/en
Application granted granted Critical
Publication of EP1601698B1 publication Critical patent/EP1601698B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy

Abstract

A protein conjugate having a prolonged in vivo half-life of a physiological activity, comprising i) a physiologically active polypeptide, ii) a non-peptidic polymer, and iii) an immunoglobulin, is useful for the development of a polypeptide drug due to the enhanced in vivo stability and prolonged half-life in blood, while reducing the possibility of inducing an immune response.
EP04720540A 2003-03-13 2004-03-13 Physiologically active polypeptide conjugate having prolonged in vivo half-life Expired - Lifetime EP1601698B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20030015744 2003-03-13
KR2003015744 2003-03-13
KR20030036408 2003-06-05
KR2003036408 2003-06-05
PCT/KR2004/000535 WO2004081053A1 (en) 2003-03-13 2004-03-13 Physiologically active polypeptide conjugate having prolonged in vivo half-life

Publications (3)

Publication Number Publication Date
EP1601698A1 EP1601698A1 (en) 2005-12-07
EP1601698A4 true EP1601698A4 (en) 2006-05-03
EP1601698B1 EP1601698B1 (en) 2009-03-11

Family

ID=36096009

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04720540A Expired - Lifetime EP1601698B1 (en) 2003-03-13 2004-03-13 Physiologically active polypeptide conjugate having prolonged in vivo half-life

Country Status (16)

Country Link
US (2) US20050176108A1 (en)
EP (1) EP1601698B1 (en)
JP (1) JP4481980B2 (en)
KR (1) KR100567902B1 (en)
CN (2) CN102757505B (en)
AT (1) ATE425188T1 (en)
AU (1) AU2004220163B2 (en)
BR (1) BRPI0408331B8 (en)
CA (1) CA2519059C (en)
DE (1) DE602004019887D1 (en)
ES (1) ES2324298T3 (en)
HK (1) HK1177465A1 (en)
IL (1) IL170685A (en)
PT (1) PT1601698E (en)
RU (1) RU2312868C2 (en)
WO (1) WO2004081053A1 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1682584B1 (en) * 2003-11-13 2013-04-17 Hanmi Science Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
KR101100059B1 (en) * 2004-06-30 2011-12-29 넥타르 테라퓨틱스 Polymer-factor ix moiety conjugates
PL1824988T3 (en) * 2004-11-12 2018-01-31 Bayer Healthcare Llc Site-directed modification of fviii
MX2007007877A (en) * 2004-12-27 2007-08-21 Baxter Int Polymer-von willebrand factor-conjugates.
KR100754667B1 (en) 2005-04-08 2007-09-03 한미약품 주식회사 Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same
AU2006239315B2 (en) 2005-04-28 2012-03-01 Ventana Medical Systems, Inc. Enzymes conjugated to antiobodies via a PEG heterobifuctional linker
AU2006250068A1 (en) * 2005-05-26 2006-11-30 Schering Corporation Interferon-IGG fusion
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007049941A1 (en) * 2005-10-27 2007-05-03 Peptron Co., Ltd Bioactive substance carrier for in vivo stable delivery tehreof, conjugate containing the same, and method of in vivo stable delivery of the bioactive substance
ES2804129T3 (en) 2005-11-23 2021-02-03 Ventana Med Syst Inc Antibody-enzyme conjugate
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR20080108147A (en) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 Pegylated factor viii
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP3896090B1 (en) 2006-06-14 2022-01-12 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP3231440A1 (en) 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
EP2162464A1 (en) * 2007-06-06 2010-03-17 Boehringer Ingelheim International GmbH Natriuretic fusion proteins
AU2008290217B2 (en) 2007-08-20 2013-09-05 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
EP2214700A4 (en) * 2007-11-02 2012-08-22 Janssen Biotech Inc Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
JP5546107B2 (en) * 2008-04-17 2014-07-09 国立大学法人宇都宮大学 RNA virus BmMLV negative silkworm cultured cell line
EP2268807A2 (en) 2008-04-21 2011-01-05 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
JPWO2010074082A1 (en) * 2008-12-24 2012-06-21 塩野義製薬株式会社 Vasohibin modification
CN101585864B (en) * 2009-01-05 2011-11-09 天津派格生物技术有限公司 Nitrogen-terminal fixed-point coupling method for colony stimulating factor of column chromatography granulocyte and coupled product
CN116925238A (en) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 Extended recombinant polypeptides and compositions comprising the same
CN102369209B (en) * 2009-03-20 2015-06-10 韩美科学株式会社 Method for preparing a site-specific physiologically active polypeptide conjugate
CN102741422B (en) 2009-08-24 2016-06-08 阿穆尼克斯运营公司 Factor VII composition and preparation and application thereof
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
HUE034398T2 (en) 2010-01-19 2018-02-28 Hanmi Science Co Ltd Liquid formulations for long-acting g-csf conjugate
JP5638628B2 (en) * 2010-01-19 2014-12-10 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． Long-acting erythropoietin conjugate solution
US20120328589A1 (en) * 2010-03-02 2012-12-27 Ilya Ruderfer Glucocerebrosidase multimers and uses thereof
KR101337797B1 (en) * 2010-07-14 2013-12-06 한미사이언스 주식회사 A liquid formulation of long acting human growth hormone conjugate
KR101382593B1 (en) * 2010-07-21 2014-04-10 한미사이언스 주식회사 Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
KR101303388B1 (en) * 2010-10-26 2013-09-03 한미사이언스 주식회사 Liquid formulations of long acting interferon alpha conjugate
US20130295052A1 (en) * 2010-11-19 2013-11-07 Manu Chaudhary Novel conjugates for targeted drug delivery
KR101309566B1 (en) * 2010-12-10 2013-09-17 포항공과대학교 산학협력단 Hyaluronic acid-protein conjugate, and preparation method thereof
SI3272861T1 (en) 2011-01-20 2020-06-30 Protalix Ltd. Alpha-galactosidase compositions
CN102309765B (en) * 2011-02-28 2013-10-16 北京韩美药品有限公司 Long-acting anticoagulant polypeptide including immunoglobulin Fc segments as carriers and preparation method of same
RU2502803C2 (en) * 2011-05-20 2013-12-27 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") PLASMID FOR EXPRESSION IN CELLS OF BACTERIUM BELONGING TO Escherichia CLASS, NON-ACTIVE PREDECESSOR OF DNase I OF HUMAN OR ITS MUTEINS; BACTERIUM BELONGING TO Escherichia CLASS, - PRODUCER OF NON-ACTIVE PREDECESSOR OF RECOMBINANT DNase I OF HUMAN OR ITS MUTEIN; PREDECESSOR OF RECOMBINANT DNase I OF HUMAN OR ITS MUTEIN; METHOD FOR OBTAINING RECOMBINANT DNase I OF HUMAN OR ITS MUTEIN; METHOD FOR OBTAINING CONJUGATES OF POLYETHYLENE GLYCOL AND RECOMBINANT MUTEIN OF HUMAN DNase I, FERMENTATIVE ACTIVE CONJUGATE OF MUTEIN OF RECOMBINANT DNase I OF HUMAN
UA113626C2 (en) * 2011-06-02 2017-02-27 A COMPOSITION FOR THE TREATMENT OF DIABETES CONTAINING THE DURABLE INSULIN CON conjugate AND THE DUAL ACTION INSULINOTROPIC PIPIDE
CN102807619B (en) * 2011-06-03 2016-08-03 北京韩美药品有限公司 Containing immunoglobulin Fc segments and the complex of granulocyte-macrophage colony stimutaing factor and pharmaceutical composition thereof
CN102313773B (en) * 2011-07-29 2013-11-20 首都师范大学 Method for identifying quantity of cysteine in protein and application thereof
CA2847837A1 (en) * 2011-09-05 2013-03-14 Hanmi Science Co., Ltd. A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate
KR20130049671A (en) 2011-11-04 2013-05-14 한미사이언스 주식회사 Method for preparation of biological active polypeptide conjugate
CN103172745A (en) * 2011-12-21 2013-06-26 北京韩美药品有限公司 Long-acting human endothelium chalone containing immune globulin Fc segment
KR102041412B1 (en) 2011-12-30 2019-11-11 한미사이언스 주식회사 Derivatives of Immunglobulin Fc fragment
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
JP6256882B2 (en) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド Factor VIII composition, and method of making and use of the composition
JP6383666B2 (en) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド Recombinant factor VIII protein
AR090281A1 (en) 2012-03-08 2014-10-29 Hanmi Science Co Ltd IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
CN103235136B (en) * 2012-04-28 2014-12-10 淄博高新区云桥生物技术研究所 Protein medicine three-dimensional conformation antibody array sequence detection method
US9902753B2 (en) * 2012-06-05 2018-02-27 Cj Healthcare Corporation Method of purifying a long-acting human growth hormone
AR091902A1 (en) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF A PROLONGED INSULIN CONJUGATE
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
AR094821A1 (en) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF AN INSULINOTROPIC PEPTIDE CONJUGATE OF PROLONGED ACTION
WO2014073842A1 (en) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
CA2901225C (en) 2013-03-08 2023-09-19 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
CN103257237B (en) * 2013-05-09 2015-05-20 中国农业大学 In-vitro detection method of allergen in food
AR096890A1 (en) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd CONJUGATING FC OF IMMUNOGLOBULINA, THAT MAINTAINS THE UNION AFFINITY OF THE FC FRAGMENT OF THE IMMUNOGLOBULIN TO FCRN
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2015046974A1 (en) 2013-09-27 2015-04-02 한미약품 주식회사 Sustained type human growth hormone preparation
EP4212180A1 (en) 2013-12-18 2023-07-19 The Scripps Research Institute Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EP3098235A4 (en) * 2014-01-20 2017-10-18 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
KR102418477B1 (en) 2014-12-30 2022-07-08 한미약품 주식회사 Gluagon Derivatives
CN107580499A (en) * 2015-03-17 2018-01-12 欧姆尼奥克斯公司 Pass through the O2 delivering regulation tumor immunities of protein mediation
BR112018002150A2 (en) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc factor ix fusion proteins and methods of manufacturing and using them
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN107759694B (en) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 Bispecific antibody, preparation method and application thereof
CN106279437B (en) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes
RU2656140C2 (en) * 2016-11-14 2018-05-31 Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России Method for obtaining a hybrid protein containing a fused protein analogue of an interferon gamma conjugated with oligosaccharide
US20200283492A1 (en) * 2017-09-29 2020-09-10 Hanmi Pharm Co., Ltd. Long acting protein complex having an enhanced efficiency
CN108164700B (en) * 2017-12-27 2020-05-08 暨南大学 Active oxygen responsive nano carrier for conveying hydrophobic drugs and preparation method thereof
GB201801902D0 (en) * 2018-02-06 2018-03-21 Stichting Katholieke Univ Immunomodulatory nanofilaments
KR101974305B1 (en) * 2018-02-14 2019-04-30 한미사이언스 주식회사 Method for preparation of biological active polypeptide conjugate
US11267858B2 (en) * 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
WO2021075526A1 (en) * 2019-10-17 2021-04-22 Ｊｃｒファーマ株式会社 Method for producing fusion protein of serum albumin and growth hormone
WO2021261712A1 (en) * 2020-06-26 2021-12-30 Sunbio, Inc. Hemoglobin derivative co-conjugated with fatty acid-linked peg and alkoxy peg as a blood substitute

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4232119A (en) * 1977-03-04 1980-11-04 Pharmacia Diagnostics Ab Reagent for use in immunochemical assay methods
US5045312A (en) * 1985-02-18 1991-09-03 Burroughs Wellcome Co. Physiologically active compositions of growth hormone and serum albumin or Ig G
WO1992016221A1 (en) * 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
US5216130A (en) * 1990-05-17 1993-06-01 Albany Medical College Complex for in-vivo target localization
EP0622082A1 (en) * 1992-07-28 1994-11-02 Toray Industries, Inc. Immunocomplex
US5492821A (en) * 1990-11-14 1996-02-20 Cargill, Inc. Stabilized polyacrylic saccharide protein conjugates
US5601825A (en) * 1988-04-01 1997-02-11 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US20010028881A1 (en) * 1999-05-28 2001-10-11 Academia Sinica Monoclonal antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
WO2003049684A2 (en) * 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487325A (en) * 1982-07-06 1984-12-11 Owens-Illinois, Inc. Crown closures and containers
KR0172969B1 (en) * 1991-04-17 1999-02-01 삐에르 까스뗄 Water-soluble polypeptides having high affinity for interferon alpha and beta
ATE267255T1 (en) * 1995-12-27 2004-06-15 Genentech Inc WHETHER PROTEIN DERIVATIVES WITH EXTENDED HALF-LIFE
ATE369384T1 (en) * 1999-05-19 2007-08-15 Emd Lexigen Res Ct Corp EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS FC FUSION PROTEINS
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
EP1200124B1 (en) 1999-07-13 2008-09-10 Bolder Biotechnology, Inc. Erythropoietin-immunoglobulin fusion proteins
AU7741000A (en) * 1999-09-30 2001-04-30 Icos Corporation Chitinase immunoglobulin fusion products
CA2499075A1 (en) * 2002-09-16 2004-03-25 Elusys Therapeutics, Inc. Production of bispecific molecules using polyethylene glycol linkers
US7217845B2 (en) * 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4232119A (en) * 1977-03-04 1980-11-04 Pharmacia Diagnostics Ab Reagent for use in immunochemical assay methods
US5045312A (en) * 1985-02-18 1991-09-03 Burroughs Wellcome Co. Physiologically active compositions of growth hormone and serum albumin or Ig G
US5601825A (en) * 1988-04-01 1997-02-11 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US5216130A (en) * 1990-05-17 1993-06-01 Albany Medical College Complex for in-vivo target localization
US5492821A (en) * 1990-11-14 1996-02-20 Cargill, Inc. Stabilized polyacrylic saccharide protein conjugates
WO1992016221A1 (en) * 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
EP0622082A1 (en) * 1992-07-28 1994-11-02 Toray Industries, Inc. Immunocomplex
US20010028881A1 (en) * 1999-05-28 2001-10-11 Academia Sinica Monoclonal antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
WO2003049684A2 (en) * 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AIMEE GUIDER PAIGE ET AL: "PROLONGED CIRCULATION OF RECOMBINANT HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR BY COVALENT LINKAGE TO ALBUMIN THROUGH A HETEROBIFUNCTIONAL POLYETHYLENE GLYCOL", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 12, no. 12, December 1995 (1995-12-01), pages 1883 - 1888, XP009062580, ISSN: 0724-8741 *

Also Published As

Publication number Publication date
CN102757505A (en) 2012-10-31
ES2324298T3 (en) 2009-08-04
EP1601698B1 (en) 2009-03-11
BRPI0408331A8 (en) 2016-06-07
JP4481980B2 (en) 2010-06-16
BRPI0408331A (en) 2006-03-21
HK1177465A1 (en) 2013-08-23
IL170685A (en) 2012-05-31
KR20040081378A (en) 2004-09-21
US20100105869A1 (en) 2010-04-29
BRPI0408331B1 (en) 2019-09-17
RU2312868C2 (en) 2007-12-20
BRPI0408331B8 (en) 2021-05-25
ATE425188T1 (en) 2009-03-15
CN102757505B (en) 2015-10-07
CA2519059C (en) 2012-12-18
AU2004220163A1 (en) 2004-09-23
US20050176108A1 (en) 2005-08-11
CN1761684A (en) 2006-04-19
US8163889B2 (en) 2012-04-24
JP2007528346A (en) 2007-10-11
DE602004019887D1 (en) 2009-04-23
EP1601698A1 (en) 2005-12-07
WO2004081053A1 (en) 2004-09-23
IL170685A0 (en) 2009-02-11
PT1601698E (en) 2009-06-17
AU2004220163B2 (en) 2008-01-31
CA2519059A1 (en) 2004-09-23
KR100567902B1 (en) 2006-04-04
RU2005128504A (en) 2006-03-10

Similar Documents

Publication Publication Date Title
HK1177465A1 (en) Physiologically active polypeptide conjugate having prolonged in vivo half- life
MXPA05007210A (en) Protein complex using immunoglobulin fragment andmethod for the preparation thereof.
ATE252601T1 (en) LONG-ACTING INSULINOTROPE PEPTIDES
DE60039629D1 (en) USE OF PHARMACEUTICAL PREPARATIONS CONTAINING OXCARBAZEPINE IN SO FAR CONDITION
TW200711657A (en) Pharmaceutical composition comprising botulinum toxin and recombinant human serum albumin
TNSN00206A1 (en) Method for treating diabetes
MXPA05013564A (en) Fusion proteins.
DE60109949D1 (en) SURGICAL HEAD FRAME WITH SOFT CONTACT SUPPORTS FOR STEREOTAKTIC SYSTEM
ATE432689T1 (en) SUSTAINED RELEASE DRUG FORMULATIONS CONTAINING A CARRIER PEPTIDE
DE69804974T2 (en) OPIOID CONJUGATES WITH ENDOGENIC CARRIER PROTEINS
LT2002063A (en) Low-dose metformin and gliburide combinations for treating diabetes
NZ507203A (en) Use of dexmedetomidine for ICU sedation
AU2003207417A1 (en) Use of tryptophan rich peptides
BR0213821A (en) Polymer / peptide conjugates Thymosin alfa 1
SE9703775L (en) Preparation of glucose-containing sterial solutions
HUP0400340A2 (en) Methods for reducing immunogenicity of polypeptides
CA2373252A1 (en) Long lasting anti-angiogenic peptides
TWI263502B (en) Pharmaceutical preparation for treating ischemic disease of heart or limbs
Smits et al. Acute effects of flosequinan (BTS 49465) in untreated moderate to severe hypertension
MD1474F1 (en) Method of treatment of the puerperal endometritis
WO2001045741A3 (en) Methods for preparing pharmaceutical formulations
TR200301916T4 (en) Transdermal therapeutic system for parkinson's disease including high plasma levels of rotigotine.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050831

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20060322

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/48 20060101ALI20060316BHEP

Ipc: C07K 19/00 20060101AFI20040928BHEP

Ipc: C07K 14/00 20060101ALI20060316BHEP

Ipc: C07K 16/00 20060101ALI20060316BHEP

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LIM, CHANG-KI

Inventor name: KIM, DAE-JIN

Inventor name: LEE, GWAN-SUN

Inventor name: KWON, SE-CHANG

Inventor name: BAE, SUNG-MIN

Inventor name: KIM, YOUNG-MIN,MAEHWAMAEUL WOONAM DREAM VALLEY 102

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BUECHEL, KAMINSKI & PARTNER PATENTANWAELTE ESTABLI

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004019887

Country of ref document: DE

Date of ref document: 20090423

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20090608

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090311

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090311

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090311

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2324298

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090311

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090311

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: HANMI PHARM. CO., LTD.

Free format text: HANMI PHARM. CO., LTD.#893-5 HAJEO-RI, PALTAN-MYEON#HWASEONG-GUN, KYUNGKI-DO 445-910 (KR) -TRANSFER TO- HANMI PHARM. CO., LTD.#893-5 HAJEO-RI, PALTAN-MYEON#HWASEONG-GUN, KYUNGKI-DO 445-910 (KR)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090311

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090331

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090311

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090311

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090311

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090313

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090611

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090311

26N No opposition filed

Effective date: 20091214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090612

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: HANMI HOLDINGS CO., LTD.

Free format text: HANMI PHARM. CO., LTD.#893-5 HAJEO-RI, PALTAN-MYEON#HWASEONG-GUN, KYUNGKI-DO 445-910 (KR) -TRANSFER TO- HANMI HOLDINGS CO., LTD.##45, BANGI-DONG, SONGPA-GU#SEOUL 138-828 (KR)

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Owner name: HANMI HOLDINGS CO., LTD., KR

Effective date: 20110117

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20110210 AND 20110216

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004019887

Country of ref document: DE

Owner name: HANMI SCIENCE CO., LTD., KR

Free format text: FORMER OWNER: HANMI PHARM. CO., LTD., KYUNGKI, KR

Effective date: 20110214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090313

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: HANMI HOLDINGS CO.,LTD

Effective date: 20110425

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090912

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090311

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004019887

Country of ref document: DE

Owner name: HANMI SCIENCE CO., LTD., KR

Free format text: FORMER OWNER: HANMI HOLDINGS CO., LTD., SEOUL, KR

Effective date: 20120531

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004019887

Country of ref document: DE

Representative=s name: BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBB -, DE

Effective date: 20120531

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004019887

Country of ref document: DE

Representative=s name: BOEHMERT & BOEHMERT, DE

Effective date: 20120531

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: HANMI SCIENCE CO., LTD.

Free format text: HANMI HOLDINGS CO., LTD.##45, BANGI-DONG, SONGPA-GU#SEOUL 138-828 (KR) -TRANSFER TO- HANMI SCIENCE CO., LTD.#550, DONGTANGIHEUNG-RO, DONGTAN-MYEON HWASEONG-SI#GYEONGGI-DO 445-813 (KR)

Ref country code: CH

Ref legal event code: NV

Representative=s name: KAMINSKI HARMANN PATENTANWAELTE EST.

REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

Owner name: HANMI SCIENCE CO. LTD, KR

Effective date: 20121003

Ref country code: FR

Ref legal event code: CA

Effective date: 20121003

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: HANMI SCIENCE CO., LTD.

Effective date: 20150521

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20221220

Year of fee payment: 20

Ref country code: SE

Payment date: 20221221

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20221221

Year of fee payment: 20

Ref country code: BE

Payment date: 20221220

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230104

Year of fee payment: 20

Ref country code: IT

Payment date: 20221221

Year of fee payment: 20

Ref country code: GB

Payment date: 20230105

Year of fee payment: 20

Ref country code: DE

Payment date: 20221220

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230412

Year of fee payment: 20

Ref country code: CH

Payment date: 20230401

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 602004019887

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20240313

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240402

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20240312

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240314